Back to Search Start Over

Targeted long-read sequencing identifies missing pathogenic variants in unsolved Werner syndrome cases.

Authors :
Miller DE
Lee L
Galey M
Kandhaya-Pillai R
Tischkowitz M
Amalnath D
Vithlani A
Yokote K
Kato H
Maezawa Y
Takada-Watanabe A
Takemoto M
Martin GM
Eichler EE
Hisama FM
Oshima J
Source :
Journal of medical genetics [J Med Genet] 2022 May 09. Date of Electronic Publication: 2022 May 09.
Publication Year :
2022
Publisher :
Ahead of Print

Abstract

Background: Werner syndrome (WS) is an autosomal recessive progeroid syndrome caused by variants in WRN . The International Registry of Werner Syndrome has identified biallelic pathogenic variants in 179/188 cases of classical WS. In the remaining nine cases, only one heterozygous pathogenic variant has been identified.<br />Methods: Targeted long-read sequencing (T-LRS) on an Oxford Nanopore platform was used to search for a second pathogenic variant in WRN . Previously, T-LRS was successfully used to identify missing variants and analyse complex rearrangements.<br />Results: We identified a second pathogenic variant in eight of nine unsolved WS cases. In five cases, T-LRS identified intronic splice variants that were confirmed by either RT-PCR or exon trapping to affect splicing; in one case, T-LRS identified a 339 kbp deletion, and in two cases, pathogenic missense variants. Phasing of long reads predicted all newly identified variants were on a different haplotype than the previously known variant. Finally, in one case, RT-PCR previously identified skipping of exon 20; however, T-LRS did not detect a pathogenic DNA sequence variant.<br />Conclusion: T-LRS is an effective method for identifying missing pathogenic variants. Although limitations with computational prediction algorithms can hinder the interpretation of variants, T-LRS is particularly effective in identifying intronic variants.<br />Competing Interests: Competing interests: DEM has received travel support from Oxford Nanopore Technologies (ONT) to speak on their behalf. DEM is a paid consultant for and holds stock options in MyOme. DEM and EEE are engaged in a research agreement with ONT. EEE is a scientific advisory board (SAB) member of Variant Bio, Inc.<br /> (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)

Details

Language :
English
ISSN :
1468-6244
Database :
MEDLINE
Journal :
Journal of medical genetics
Publication Type :
Academic Journal
Accession number :
35534204
Full Text :
https://doi.org/10.1136/jmedgenet-2022-108485